Tagged Articles

Bayer 117 articles

Mirena IUD side effect lawsuits expected to grow into hundreds

mirena IUD

Sarah says her experience with Mirena IUD for birth control was so horrendous that she would never recommend the device to anyone. The mother of three says she felt pain the minute the intrauterine device was inserted. The pain got so bad she went to the emergency room where doctors told her she would have to have her IUD removed as soon as possible. The device had perforated her uterus and floated into her abdomen. She had to undergo surgery to remove it. It was a frightening experience, but one that is being reported more and more with the T-shaped, ... Read More

Woman recounts nightmare experience with Mirena IUD

mirena IUD

It was difficult to see the “cons” with the Mirena IUD, writes Bianca Wordley in The Border Mail. “The small t-shaped IUD works when the hormone levonorgestrel is released, making the mucus in the cervix thicker so that sperm can’t get into the womb. It’s inserted by your doctor, isn’t expensive, requires no upkeep and, in many cases, means you won’t have a period for its recommended duration of five years. Sounds brilliant, doesn’t it? For many it is,” she writes. “In my case, however, it was a dreadful mistake.” Within the first three months after she had the device inserted, ... Read More

Affordable Healthcare Act may make more women choose IUDs over pills

IUD iStock

Changes in health care laws may help make intrauterine devices (IUDs) more affordable for women, and could boost sales of the devices in the United States. There are three types of IUDs sold in the U.S., including Bayer’s Mirena, which was introduced 12 years ago. IUDs have steep upfront costs ranging from $400 to $1,000, which have made lesser expensive birth control pills a much more attractive option. However, under the Affordable Healthcare Act, new health plans or those that lose their grandfathered status now must provide many preventative services – including birth control – without patients having to dig ... Read More

Woman’s lawsuit claims Mirena IUD caused her serious bodily injury

IUD iStock

An Arizona woman has filed a lawsuit against Bayer alleging her intrauterine device for birth control caused her serious bodily injury. Cynthia Solano had a Mirena IUD inserted in her uterus by her doctor in January 2011, and experienced cramping, pain and spotting. Her doctor repeatedly assured her that the device had been implanted properly. However, in December 2012, the day after another doctor visit, Solano vomited and was admitted to the hospital where a CT scan revealed the IUD had become embedded in her body. She was diagnosed with renal failure and a slow heartbeat. Solano had to undergo ... Read More

Bayer introduces new hormone-releasing IUD Skyla

IUD

The Food and Drug Administration (FDA) has approved a new contraceptive device  made by Bayer HealthCare Pharmaceuticals. Skyla, an intrauterine device (IUD) that releases the hormone levonorgestrel, is placed in the uterus to prevent pregnancy for up to three years. Skyla was found to be more than 99 percent effective at preventing pregnancy and is an attractive contraception alternative to the birth control pill, which must be taken daily. The device is a small, flexible plastic T-shaped device containing 13.5 mg of the progestin hormone levonorgestrel. Because Skyla slowly releases levonorgestrel into the uterus, only small amounts of the hormone ... Read More

Anti-clotting drug Eliquis gets FDA approval

blood cells

Eliquis, a new anti-clotting drug developed by Bristol-Myers Squibb and Pfizer as an alternative to the decades-old warfarin (Coumadin), has finally won approval from the U.S. Food and Drug Administration (FDA). Last June, federal regulators rejected the blood-thinning drug, designed for the prevention of strokes in patients with atrial fibrillation, on the basis that they needed more information from a major clinical trial about the drug’s safety and efficacy. The FDA’s rejection of Eliquis dealt a blow to it developers, who were poised to capture a lion’s share of the market from warfarin at a time when competing drugs were ... Read More

Bayer expects to reap billions from new blood thinner Xarelto

blood cells

Bayer is banking on five of its prescription drugs to bring in more than $7 million in annual sales, including its blood thinner Xarelto (rivaroxaban), which is approved for various uses in 120 countries, including the United States. Bayer also expects stellar performances from colorectal cancer drug Stivarga (regorafenib); Alpharadin (radium-223 chloride), an experimental radiopharmaceutical for bone cancer metastases; macular degeneration drug Eylea (afibercept), and experimental pulmonary hypertension treatment riciguat. Bayer says that the blood thinner Xarelto has the strongest potential of the lot and could generate sales of more than $2.5 billion on its own. The medication is approved ... Read More

FDA grants new indication for blood thinner Xarelto

blood cells

The Food and Drug Administration (FDA) has agreed to expand the indication for Bayer and Johnson & Johnson’s new blood thinner Xarelto. The drug can now be used to treat and prevent deep vein thrombosis and pulmonary embolism. Xarelto is already approved for three uses – for reducing the risk of blood clots in patients who have had knee replacement surgery and patients who have had hip replacement surgery, and for the prevention of strokes in patients with the common heart rhythm abnormality, atrial fibrillation. The drug companies reported last week that sales for the drug have already more than ... Read More

Xarelto makers enjoy huge profits despite bleeding risks

blood cells

Sales of the blood thinner Xarelto have more than quadrupled compared to prior year quarter to $105 million, and were up $88 million in the second quarter, according to Bayer. Xeralto, a joint effort by Bayer and Johnson & Johnson, is used to prevent deep vein thrombosis and pulmonary embolism in patients who are having hip replacement or knee replacement surgery. In late 2011, it became one of the first blood thinners since the long-used warfarin for the prevention of strokes in patients with a common but life threatening heart rhythm abnormality known as atrial fibrillation. A year before Xeralto ... Read More

FDA to decide fate of blood thinner Eliquis by March

blood cells

The Food and Drug Administration (FDA) says it will decide by March 17, 2013, whether to approve Bristol-Myers Squibb Co and Pfizer Inc.’s blood thinner Eliquis for the prevention of strokes in patients with atrial fibrillation. Drug regulators rejected Eliquis last June, telling the drug’s makers that it needed more information on a pivotal clinical trial before it could gauge its safety and efficacy. Atrial fibrillation is a common but dangerous form of irregular heartbeat. The condition can cause blood clots that can travel to the brain and cause strokes. Blood thinners are prescribed for atrial fibrillation patients to prevent ... Read More